J&J’s Imaavy gains first-in-class label for warm autoimmune hemolytic anemia

J&J announced that its monoclonal antibody Imaavy has received a label expansion in the United States.

The expanded indication makes Imaavy the first therapy approved specifically for warm autoimmune hemolytic anemia, a rare condition where autoantibodies destroy red blood cells, leading to severe anemia and fatigue.

The regulatory decision follows earlier approvals of the drug in Japan, where two separate indications were cleared earlier this year.

The new label could broaden the patient population eligible for treatment and may influence market dynamics for hemolytic anemia therapies.